Core Viewpoint - Tianjin Pharmaceutical Co., Ltd. (referred to as "the company") has disclosed a regulatory rectification report addressing previous violations identified by the Tianjin Securities Regulatory Bureau, including internal control deficiencies and the issuance of warning letters to five executives [1][2]. Regulatory Issues - The company faced two main violations: unclear contractual obligations in external technology projects and failure to identify risks in research projects, leading to delays in recovering advance payments. These actions violated the "Corporate Governance Guidelines for Listed Companies" and "Guidelines for Internal Control Applications" [2]. - In response, the company established a special rectification working group to implement corrective measures, including revising contract management processes and enhancing risk control mechanisms for research projects [2][3]. Financial Performance - In 2024, the company reported revenue of 3.215 billion yuan, a 15.0% decrease year-on-year, while net profit increased by 14.01% to 133 million yuan, primarily due to a significant reduction in sales expenses [6]. - Sales expenses dropped dramatically by 45.76% to 570 million yuan, with promotional activity costs falling by 54.23% and market planning service fees decreasing by 60.03% [6]. - However, in 2025, the company faced increased financial pressure, with revenue for the first three quarters amounting to 2.232 billion yuan, a 13.24% decline, and net profit down 62.75% to approximately 69.54 million yuan [6][7]. Legal and Compliance Challenges - The company has been penalized multiple times for monopolistic practices, with total fines exceeding 170 million yuan. A notable case involved a price increase of 62.5% for a key product, resulting in a fine of approximately 69.19 million yuan, which accounted for 51.85% of its net profit for 2024 [4][5]. - The cumulative impact of these penalties has significantly affected the company's cash flow and profitability, highlighting the challenges posed by regulatory compliance and market competition [7].

Core Viewpoint - Guizhou Bailing has undergone significant changes, including a stock name change from "ST Bailing" to "Guizhou Bailing" after successfully turning around its financial performance, but it still faces ongoing regulatory scrutiny from the China Securities Regulatory Commission (CSRC) due to an investigation into information disclosure violations [1][2]. Financial Performance - In 2024, Guizhou Bailing reported a revenue of 3.825 billion yuan, a decrease of 10.26% year-on-year, while net profit reached 33.62 million yuan, an increase of 108.11% compared to the previous year [2][3]. - The company’s non-recurring net profit was -82.44 million yuan, but this figure still represented an increase of 81.33% year-on-year [2]. Regulatory Issues - The company received a notice from the CSRC on November 8, 2024, indicating that it is under investigation for suspected violations of information disclosure laws, with no conclusive opinions or decisions received as of June 26, 2024 [1][2]. - During a performance briefing on May 12, 2024, investors expressed concerns about the ongoing investigation and potential delisting risks, but the company did not provide a direct answer [2]. Market Conditions - The decline in revenue for 2024 was attributed to a significant stockpiling of cold and flu medications by consumers in the previous year, which led to a depletion of demand in 2024, alongside a general decrease in pharmaceutical prices [3]. - The company reported a 17.76% decrease in costs compared to 2023, primarily due to lower prices of key raw materials such as forsythia and honeysuckle, resulting in an improved gross margin [3].